Nanogen

What is Nanogen?

Nanogen, Inc. was a diagnostics company founded in 1993, known for developing, manufacturing, and marketing diagnostic products aimed at the in vitro diagnostic market across the United States, Canada, and Europe. Their focus was on the creation of diagnostic test kits and reagents that utilized polymerase chain reaction (PCR) technology to serve the molecular diagnostic sector.

Their PCR molecular product lines included Q-PCR Alert products for in vitro diagnostic use, which were marketed in Italy through a contract sales force and distributed across other European countries via a network of distributors; and MGB Alert products designed for molecular diagnostics.

They also developed point-of-care products like qualitative cardiac test products for emergency care to diagnose myocardial infarction, quantitative cardiac tests to measure NT-proBNP levels for congestive heart failure diagnosis, and a pandemic influenza test capable of detecting and differentiating influenza strains, including potential pandemic strains.

Despite their innovations, on May 13, 2009, Nanogen filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware. Post-bankruptcy, the company's technology and products seem to have been integrated into ELITechGroup, a global leader in in-vitro diagnostics now part of Bruker Corporation.

ELITechGroup has a broad product portfolio that includes Molecular Diagnostics, Biomedical Systems, and Microbiology, serving hospitals and diagnostic labs in over 100 countries. They continue to innovate with high-throughput instruments for molecular diagnostics, while maintaining a commitment to service excellence in the laboratory field.